INmune Bio (NASDAQ:INMB) has been given a $13.00 target price by research analysts at Maxim Group in a research note issued on Friday, TipRanks reports. The brokerage presently has a “buy” rating on the stock. Maxim Group’s target price points to a potential upside of 109.68% from the stock’s previous close.
Separately, HC Wainwright reissued a “buy” rating and set a $11.50 target price on shares of INmune Bio in a report on Thursday.
NASDAQ:INMB traded up $0.01 during midday trading on Friday, hitting $6.20. 12,080 shares of the stock were exchanged, compared to its average volume of 37,717. INmune Bio has a one year low of $5.06 and a one year high of $11.50. The business has a 50-day moving average price of $6.88 and a two-hundred day moving average price of $8.82. The company has a debt-to-equity ratio of 0.01, a current ratio of 20.94 and a quick ratio of 20.94.
In related news, Director Scott Juda purchased 5,000 shares of the company’s stock in a transaction on Wednesday, August 21st. The shares were bought at an average price of $6.00 per share, with a total value of $30,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In the last three months, insiders have purchased 12,000 shares of company stock worth $72,990. 67.67% of the stock is owned by corporate insiders.
An institutional investor recently raised its position in INmune Bio stock. BlackRock Inc. raised its stake in INmune Bio Inc (NASDAQ:INMB) by 1,556.5% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 3,048 shares of the company’s stock after buying an additional 2,864 shares during the period. BlackRock Inc.’s holdings in INmune Bio were worth $29,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 0.36% of the company’s stock.
INmune Bio Company Profile
INmune Bio Inc, a clinical-stage immunotherapy company, focuses on engineering and harnessing the innate immune system to treat the patient's cancer. The company intends to develop and commercialize product candidates to treat diseases comprising hematologic malignancies and solid tumors. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma; and INB03 that treats patients with advanced cancers with elevated biomarkers of inflammation, including elevated levels of myeloid derived suppressor cells in their blood.
Further Reading: Limitations of the P/E Growth ratio
Receive News & Ratings for INmune Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INmune Bio and related companies with MarketBeat.com's FREE daily email newsletter.